Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Neuronetics, Inc.NASDAQ: STIM

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 69.59M shares rose 13.2% year over year, behind the +71.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +34.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.2% toward the trailing-twelve-month pace of +71.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
69.59M+1.2% QoQ
Last fiscal yearDec 2025
65.95M+107.8% YoY
LTMMar 2026
67.96M+71.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.2%——
1 year+107.8%——
3-year CAGR+34.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
65.95M USD
Year-over-year change
+107.8%
4-year CAGR
+26.8%

Weighted Avg Shares vs competitors

How STIM compares with its peers on the latest reported figures

  • STIM's LTM Mar 2026 weighted avg shares of 67.96M shares is the 5th highest of the 10 companies compared; the peer median is 54.95M shares.
  • Its year-over-year change of +71.5% is the highest of 10, against a peer median of +16.6%.
  • Over three fiscal years its annual growth of +34.8% compares with a peer median of +13.2%.
STIM Competitors Peer median
Weighted Avg Shares for STIM and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +52.9%+22.0%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
CDXSCodexis, Inc.LTM Mar 202689.2M +16.6%+10.1%
OSUROraSure Technologies, Inc.LTM Mar 202672.2M -3.1%+0.4%
STIMNeuronetics, Inc.LTM Mar 202667.96M +71.5%+34.8%
CATXPerspective Therapeutics, Inc.LTM Mar 202654.95M -21.6%+10.4%
ATLNAtlantic International Corp.LTM Dec 202554.48M +44.0%+36.2%
NYXHNyxoah S.A.LTM Mar 202639.55M +13.3%+13.9%
PROFProfound Medical Corp.LTM Mar 202631.8M +21.2%+13.2%
PREPrenetics Global LimitedLTM Mar 202615.04M +18.8%+40.5%
Peer median (excluding STIM) 54.95M+16.6%+13.2%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M65.21M71.35M74.89M149.16M
Cost of Revenue11.65M15.48M19.64M20.73M76.85M
Gross Profit43.66M49.72M51.71M54.16M72.31M
Gross Margin78.9%76.3%72.5%72.3%48.5%
Research & Development7.92M9.34M9.52M12.77M6.58M
Selling, General & Admin63.3M75.5M72.74M75.95M97.16M
Operating Expenses71.22M84.83M82.26M88.72M103.74M
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
EBITDA(26.81M)(31.96M)(22.76M)(34.37M)(27.12M)
EBITDA Margin-48.5%-49.0%-31.9%-45.9%-18.2%
Operating Income(27.56M)(35.11M)(30.55M)(34.56M)(31.44M)
Operating Margin-49.8%-53.8%-42.8%-46.2%-21.1%
Interest Income0024K00
Interest Expense3.3M3.6M5.42M7.29M8.42M
Other Income / Expenses(3.61M)(2.1M)365K(9.18M)(7.56M)
Income Before Tax(31.17M)(37.21M)(30.19M)(43.74M)(39M)
Pre-Tax Margin-56.4%-57.1%-42.3%-58.4%-26.1%
Income Tax Expense00(24K)(14K)0
Net Income(31.19M)(37.16M)(30.19M)(43.71M)(39M)
Net Margin-56.4%-57.0%-42.3%-58.4%-26.1%
EPS (Basic)(1.22)(1.38)(1.05)(1.38)(0.59)
EPS (Diluted)(1.22)(1.38)(1.05)(1.38)(0.59)
Weighted Avg Shares25.48M26.9M28.66M31.73M65.95M
Weighted Avg Shares (Diluted)25.48M26.9M28.66M31.73M65.95M

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.